Search results
Results from the WOW.Com Content Network
a phase III trial for HER2+ gastric cancer compares T-DM1 to physician's choice of taxane (docetaxel or paclitaxel). [35] On 22 October 2015, Roche and co-developer ImmunoGen disclosed that trastuzumab emtansine had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2 -positive ...
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 30 ] [ 27 ] [ 31 ] [ 32 ] It is specifically used for cancer that is HER2 receptor positive . [ 30 ]
docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide: breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. [11] It is administered by intravenous injection. [11] There is also an albumin-bound formulation. [11]
The structure of paclitaxel, a widely used mitotic inhibitor.. A mitotic inhibitor, microtubule inhibitor, or tubulin inhibitor, is a drug that inhibits mitosis, or cell division, and is used in treating cancer, gout, and nail fungus.
The pregnancy category of a medication is an assessment of the risk of fetal injury due to the pharmaceutical, if it is used as directed by the mother during pregnancy. It does not include any risks conferred by pharmaceutical agents or their metabolites in breast milk. Every drug has specific information listed in its product literature.
A 2024 cohort study of ICI use during pregnancy showed no overreporting of specific adverse effects on pregnancy, fetal, and/or newborn outcomes, interestingly. [ 158 ] Using a mouse model of bladder cancer, researchers have found that a local injection of a low dose anti-CTLA-4 in the tumour area had the same tumour inhibiting capacity as when ...